Amplia Therapeutics returns successful phase one trial results

• Results from Amplia Therapeutics’ (ATX) recent clinical trial shows its treatment for cancer and fibrosis is safe and well tolerated in all doses tested
• The study on 56 healthy volunteers focussed on the safety and tolerability of AMP945 when orally administered
• No withdrawals or serious adverse events were recorded during the trial, with a mild headache being the most common reaction
• The company is now planning its next steps for the drug, with phase two trials in pancreatic cancer expected to start towards the end of 2021
• Amplia Therapeutics last traded at 21 cents on July 20

Results from Amplia Therapeutics’ (ATX) recent clinical trial have shown its treatment for cancer and fibrosis was safe and well tolerated in all doses tested.

To view media story please click here.